SCHEMBL5535665

SCHEMBL5535665

CC1=Cc2c(C#N)nn(S(=O)(=O)c3ccc(C)cc3)c2C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
ALDH1A1 P00352 2/20 0.48
LMNA P02545 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
MAPT P10636 2/20 0.44
POLB P06746 2/20 0.38
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
PKM P14618 3/20 0.38
HSD11B1 P28845 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ALDH3A1 P30838 1/20 0.36
SLC9A1 P19634 1/20 0.36
MMP2 P08253 1/20 0.36
HTT P42858 1/20 0.36
CXCL8 P10145 1/20 0.35
GAA P10253 1/20 0.35
NOD2 Q9HC29 1/20 0.35
NOD1 Q9Y239 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5999032 0.82 MAPT (0.49) MEN1KMT2AALDH1A1LMNATDP1
SCHEMBL5530256 0.81 MEN1 (0.47) MEN1KMT2AALDH1A1LMNATDP1
SCHEMBL5523923 0.79 MEN1 (0.47) MEN1KMT2AALDH1A1LMNATDP1
SCHEMBL14597023 0.72 MEN1 (0.46) MEN1KMT2AALDH1A1LMNATDP1
SCHEMBL29597017 0.61 POLB (0.58) MEN1KMT2AALDH1A1LMNATDP1
SCHEMBL23630350 0.58 USP30 (0.53) KMT2AALDH1A1LMNAPOLBPKM
SCHEMBL16156588 0.58 PKM (0.54) MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL5056157 0.58 POLB (0.56) MEN1KMT2AALDH1A1LMNATDP1
SCHEMBL4537086 0.58 PKM (0.88) MEN1KMT2AALDH1A1LMNAPOLB
SCHEMBL10724066 0.58 PKM (0.88) MEN1KMT2AALDH1A1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070072924-A1 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof ARENA PHARMACEUTICALS, INC. 2007-03-29 US disclosed
EP-1683794-A1 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof Arena Pharmaceuticals, Inc. (US) 2006-07-26 EP disclosed
EP-1599469-B1 TETRAZOLE DERIVATIVES AND METHODS OF TREATMENT OF METABOLIC-RELATED DISORDERS THEREOF ARENA PHARM INC (US) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072924-A1 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof SQLE, ACE, AGTR2 MEN1 4578/4885KMT2A 4044/4885ALDH1A1 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.